Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KBP-5074 for uncontrolled hypertension in moderate to severe chronic kidney disease
MOH_2023-03-28_012483Phase 3Not yet recruiting
- Sponsor
- KBP Biosciences
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ocederenone in hypertension (HTN) and chronic kidney disease (CKD) (3 arms), sponsored by KBP Biosciences. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2023-03-28_012483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-28_012483.